Theriva Biologics, Inc.TOVXNYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P29
Within normal range
vs 3Y Ago
-0.3x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | -15.93% |
| 2023 | 22.08% |
| 2022 | 50.29% |
| 2021 | 52.02% |
| 2020 | -53.70% |
| 2019 | -6.43% |
| 2018 | -36.95% |
| 2017 | -35.47% |
| 2016 | -11.54% |
| 2015 | 127.11% |